Technology commercialisation company BTG will invest in Senexis, a biotechnology company that will develop treatments for ageing-related diseases such as Alzheimer's, Parkinson's and Huntington's.
Senexis, based at the University of Manchester Institute of Science and Technology, has raised ?1.4 million from BTG and Catalyst BioMedica Limited to finance its research.
Register to continue
Why register?
- Registration is free and only takes a moment
- Once registered, you can read 3 articles a month
- Sign up for our newsletter
Subscribe
Or subscribe for unlimited access to:
- Unlimited access to news, views, insights & reviews
- Digital editions
- Digital access to 罢贬贰’蝉 university and college rankings analysis
Already registered or a current subscriber?
Please or to read this article.